Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$65.76
pos +0.50
+0.77%
Today's Range: 65.29 - 66.12 | BMY Avg Daily Volume: 6,416,600
Last Update: 03/30/15 - 4:02 PM EDT
Volume: 4,145,990
YTD Performance: 10.55%
Open: $65.55
Previous Close: $65.26
52 Week Range: $46.30 - $69.20
Oustanding Shares: 1,662,118,446
Market Cap: 108,333,485,455
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.06 2.06 2.06 2.06
Latest Dividend: 0.37
Latest Dividend Yield: 2.28%
Dividend Ex-Date: 04/01/15
Price Earnings Ratio: 54.17
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
54.17 54.20 27.26
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.53% 24.71% 93.82%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 -0.25 -0.09
Net Income -21.40 -0.61 -0.27
EPS -22.20 -0.44 -0.18
Earnings for BMY:
EBITDA 3.06B
Revenue 15.88B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.49 $0.38 $1.69 $2.23
Number of Analysts 10 9 13 13
High Estimate $0.57 $0.42 $1.83 $2.58
Low Estimate $0.44 $0.34 $1.60 $1.80
Prior Year $0.46 $0.48 $1.85 $1.69
Growth Rate (Year over Year) 5.43% -21.06% -8.65% 31.82%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Here are healthcare stocks of all shares and sizes with strong charts.
Good buys kept getting overlooked.
Bullish
Mar 24, 2015 | 7:56 AM EDT
Shares of BMY now seen reaching $75, according to BMO Capital. Estimates also upped, as immune-oncology should drive growth and the com...
Bullish
Mar 05, 2015 | 8:05 AM EST
Shares of BMY now seen reaching $70, according to Credit Suisse. Estimates also increased, given the quick approval of the company's ne...
Investors may have won the skirmish but lost the battle.
Update
Feb 12, 2015 | 6:41 AM EST
Leerink Global Healthcare Conference (Day 2 of 2) - 02/11/15 - 02/12/15 New York, NY
The debate raging among investors about hepatitis C revenue declines.
After lightening up dollar-sensitive positions, I can ride out the week.
It's a positive for our markets, not a negative.
Use the overall weakness to pick up the America First stocks.

Columnist Conversations

Exxon Mobil (XOM) shares are back up near the $85.75 level. This area was solid support for about five months ...
Good closing piece by "El Capitan" on the nature of buyers these days. I totally agree. As I have recently wri...
I have covered my small SPY short that I put on today after the close at about $208.03 for a breakeven on the ...
The fact that Twitter (TWTR) "bears" had a chance to inflict more serious damage by pressing TWTR further belo...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.